Blinded vs. Unblinded Data Review Best Practices

1. Why Blinded vs. Unblinded Review Matters

Clinical trials often require intensive data review before database lock. At that point, teams need to identify missing assessments, inconsistent dates, implausible values, unresolved queries, coding issues, protocol deviations, treatment discontinuations, and other data problems. The challenge is that some of these activities must occur without revealing treatment assignment.

The purpose of blinded review is not simply to hide a treatment column. It is to prevent knowledge of treatment assignment from influencing data cleaning, endpoint interpretation, patient-level decisions, or the selection of issues that are pursued before lock. The review process should therefore be designed around an explicit information boundary.

Unblinded review has a different purpose. Once the appropriate milestone has been reached and the relevant team is authorized to see treatment-specific information, the review can focus on treatment-group patterns, treatment-specific safety findings, arm-level efficacy summaries, and issues that cannot be meaningfully evaluated without assignment information.

2. What Exactly Is a Blinded Review?

Blinded review means that a reviewer can inspect the data needed to evaluate quality and clinical coherence while treatment assignment remains concealed. The masking mechanism must be deliberate. A patient identifier that can be trivially cross-referenced to a treatment code is not an adequate firewall.

Examples of information that may remain available

• Subject identifier and site identifier.
• Visit dates and assessment dates.
• Laboratory values and reference ranges.
• Adverse-event terms, severity, seriousness, action taken, and outcome.
• Concomitant medication information.
• Disposition dates and reasons.
• Protocol deviation information.
• Exposure dates when their disclosure does not reveal assignment.
• Blinded treatment labels such as Treatment A and Treatment B only when the mapping is protected.

Information that can break the blind

• Actual treatment names or recognizable drug/device identifiers.
• Randomization codes or treatment-code mappings.
• Arm-specific labels embedded in filenames or output titles.
• Drug-specific dose schedules that uniquely identify an arm.
• Unmasked pharmacy or drug-accountability information.
• Tables in which small cell counts make the treatment mapping obvious.
• Free-text comments that identify the treatment received.

3. Roles, Responsibilities, and the Information Firewall

A robust review process starts by defining who is allowed to know what. The firewall should be documented before review begins rather than improvised when the first output is generated.

4. The Pre-Lock Review Workflow

The most effective review is staged. Attempting to perform all data review in one meeting immediately before database lock creates avoidable pressure and increases the risk that important issues are either missed or handled inconsistently.

What should happen before the final review meeting?

• All feasible data-entry queries should already have been issued.
• External data should be reconciled or formally dispositioned.
• Medical coding should be substantially complete.
• Key dates should be reconciled across relevant domains.
• Analysis populations and endpoint derivations should be stable enough to review.
• Known exceptions should be documented rather than discovered for the first time during the meeting.

5. Safety Review: What Can Be Evaluated While Blinded?

A large amount of safety review can occur without treatment assignment. The reviewer can examine whether adverse events have complete dates, appropriate seriousness and severity, correct relationship fields, coherent action taken, and appropriate outcomes.

Blinded safety review is especially valuable because it allows the reviewer to concentrate on data quality rather than treatment-group differences. The reviewer should resist the temptation to interpret apparent numerical imbalances until the appropriate unblinded stage.

6. Efficacy Review: Avoiding Treatment-Driven Interpretation

Efficacy review requires more discipline because many endpoint definitions are inherently tied to event timing. The blinded reviewer can still verify that assessments are present, dates are plausible, endpoint derivations follow the protocol, and missingness is correctly represented.

Examples of blinded efficacy checks

• Verify assessment dates against visit windows.
• Check that baseline assessments are identified according to the SAP.
• Confirm that tumor measurements have valid units and target-lesion identifiers.
• Check that progression dates do not precede required assessments.
• Verify that response derivations use the intended assessment hierarchy.
• Confirm censoring dates and reasons.
• Check that death dates are reconciled with disposition and survival datasets.

7. Data-Quality Review Across Domains

The most valuable pre-lock review often happens at the intersections between domains. A single dataset may look correct in isolation while becoming obviously inconsistent when compared with another source.

8. Programming the Review: Do Not Manually Mask Outputs

A common operational mistake is to generate a fully unblinded output and then manually replace treatment labels. This is fragile and difficult to validate. A better approach is to build masking into the program itself.

R example: creating controlled blinded treatment labels

library(dplyr)

review_data <- adsl %>%
  mutate(
    REVIEW_TRTA = case_when(
      ACTARM == "Treatment A" ~ "Treatment A",
      ACTARM == "Treatment B" ~ "Treatment B",
      TRUE ~ "Not Available"
    )
  )

# The mapping between A/B and the actual treatment is held
# separately and is not included in the review package.

SAS example: applying a blinded review label

data review_adsl;
    set adsl;

    length REVIEW_TRTA $20;

    if ACTARM = "Treatment A" then
        REVIEW_TRTA = "Treatment A";
    else if ACTARM = "Treatment B" then
        REVIEW_TRTA = "Treatment B";
    else
        REVIEW_TRTA = "Not Available";

    drop ACTARM;
run;

Review-output validation

A simple automated check can scan generated output metadata for forbidden strings. The exact implementation depends on the environment, but the principle is straightforward: treat accidental unblinding as a testable quality attribute.

forbidden <- c(
  "Placebo",
  "Active Drug",
  "Dose Level 1",
  "Dose Level 2"
)

if (any(grepl(
  paste(forbidden, collapse = "|"),
  output_text,
  ignore.case = TRUE
))) {
  stop("Potential treatment-information leakage detected.")
}

9. Documentation: The Review Log Is Part of the Control System

A review is only reproducible if someone can later determine what was reviewed, when it was reviewed, who reviewed it, what issue was identified, what decision was made, and whether that decision affected the final data.

Review documentation should distinguish between a data correction and a reviewer interpretation. The former may require a source-data change or query. The latter may simply document why the existing value is acceptable under the protocol and SAP.

10. Common Failure Modes

11. Final Database-Lock Checklist

12. A Practical Review Package

A strong review package is usually modular. The exact contents depend on the study, but the following structure works well for many interventional trials.

References and Further Reading

International Council for Harmonisation. ICH E6(R3): Guideline for Good Clinical Practice.
International Council for Harmonisation. ICH E9: Statistical Principles for Clinical Trials.
International Council for Harmonisation. ICH E3: Structure and Content of Clinical Study Reports.
U.S. Food and Drug Administration. Guidance for Industry: Computerized Systems Used in Clinical Investigations.